The DOI matches its Crossref record; 30 of the 32 references it cites were found in a registry or an index.
Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial
Open accessAbstract
BACKGROUND: GLP-1 receptor agonists have neurotrophic properties in in-vitro and in-vivo models of Parkinson's disease and results of epidemiological studies and small randomised trials have suggested possible benefits for risk and progression of Parkinson's disease. We aimed to establish whether the GLP-1 receptor agonist, exenatide, could slow the rate of progression of Parkinson's disease. METHODS: We did a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial at six research hospitals in the UK. Participants were aged 25-80 years with a diagnosis of Parkinson's disease, were at Hoehn and Yahr stage 2·5 or less when on dopaminergic treatment, and were on dopaminergic treatment for at least 4 weeks before enrolment. Participants were randomly assigned (1:1) using a web-based system with minimisation according to Hoehn and Yahr stage and study site to receive extended-release exenatide 2 mg by subcutaneous pen injection once per week over 96 weeks, or visually identical placebo. All participants and all research team members at study sites were masked to randomisation allocation. The primary outcome was the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III score, off dopaminergic medication at 96 weeks, analysed in the intention-to-treat population using a linear mixed modelling approach. This study is registered with ISRCTN (14552789), EudraCT (2018-003028-35), and ClinicalTrials.gov (NCT04232969). FINDINGS: Between Jan 23, 2020, and April 23, 2022, 215 participants were screened for eligibility, of whom 194 were randomly assigned to exenatide (n=97) or placebo (n=97). 56 (29%) participants were female and 138 (71%) were male. 92 participants in the exenatide group and 96 in the placebo group had at least one follow-up visit and were included in analyses. At 96 weeks, MDS-UPDRS III OFF-medication scores had increased (worsened) by a mean of 5·7 points (SD 11·2) in the exenatide group, and by 4·5 points (SD 11·4) points in the placebo group (adjusted coefficient for the effect of exenatide 0·92 [95% CI -1·56 to 3·39]; p=0·47). Nine (9%) participants in the exenatide group had at least one serious adverse event compared with 11 (11%) in the placebo group. INTERPRETATION: Our findings suggest that exenatide is safe and well tolerated. We found no evidence to support exenatide as a disease-modifying treatment for people with Parkinson's disease. Studies with agents that show better target engagement or in specific subgroups of patients are needed to establish whether there is any support for the use of GLP-1 receptor agonists for Parkinson's disease. FUNDING: National Institute for Health and Care Research and Cure Parkinson's.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“however, this decline was not confirmed in a study using exenatide once weekly 105 or in another recent trial of NLY01, a brainpenetrant, pegylated exenatide. 106”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [105]
The cited source says what the claim attributes to it.
In the citing paper
“A phase III trial evaluating 96 weeks of once-weekly exenatide treatment in people with Parkinson’s disease also found no disease-modifying benefits for MDS-UPDRS part III scores (55).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Systematic review of levodopa dose equivalency reporting in Parkinson's disease
Tomlinson, C. L., Stowe, R., Patel, S., Rick, C., Gray, R., & Clarke, C. E. (2010) · Movement Disorders · doi:10.1002/mds.23429 · Cited by 4,219
Bloem, B. R., Okun, M. S., & Klein, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00218-x · Cited by 3,920
Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease
Yun, S. P., Kam, T.-I., Panicker, N., Kim, S., Oh, Y., Park, J.-S., Kwon, S.-H., Park, Y. J., Karuppagounder, S. S., Park, H., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0051-5 · Cited by 1,123
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889
Self-citationExenatide and the treatment of patients with Parkinson's disease
Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68295 · Cited by 529
Self-citationRossi, M., Candelise, N., Baiardi, S., Capellari, S., Giannini, G., Orrù, C. D., Antelmi, E., Mammana, A., Hughson, A. G., Calandra-Buonaura, G., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02160-8 · Cited by 451 · cited 1×
“…between the groups for the primary and secondary outcomes and included fixed effects for treatment, baseline MDS-UPDRS part III OFF-medication scores, time (24, 48, 72, and 96 weeks) as a categorical variable, treatment and time interaction, and the minimisation factor Hoehn and Yahr status.”
Groveman, B. R., Orrù, C. D., Hughson, A. G., Raymond, L. D., Zanusso, G., Ghetti, B., Campbell, K. J., Safar, J., Galasko, D., & Caughey, B. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0508-2 · Cited by 421
Progress towards therapies for disease modification in Parkinson's disease
Vijiaratnam, N., Simuni, T., Bandmann, O., Morris, H. R., & Foltynie, T. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00061-2 · Cited by 419
Self-citationProtection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4
Perry, T., Haughey, N. J., Mattson, M. P., Egan, J. M., & Greig, N. H. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.037481 · Cited by 380
Self-citation
Cited by
GLP-1-based therapies for diabetes, obesity and beyond
Drucker, D. J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01183-8 · Cited by 236
“No benefit of exenatide therapy was detected at 96 weeks on the primary end-point using clinical rating scales to assess changes in motor and non-motor indices of Parkinson disease activity 140 .”
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits
Wong, C. K., & Drucker, D. J. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194751 · Cited by 112
“Thus, while endocardial endothelial cells represent a plausible target for the antiinflammatory actions of GLP-1 medicines locally in both species, these medicines may also exert cardioprotective effects directly on human cardiomyocytes.”
The expanding landscape of GLP-1 medicines
Drucker, D. J. (2026) · Nature Medicine · doi:10.1038/s41591-025-04124-5 · Cited by 81
“Five clinical trials assessed the efficacy of exenatide or its derivatives in the treatment of Parkinson’s disease in addition to dopaminergic medication 42–46 .”
West, J., Li, M., Wong, S., Le, G. H., Teopiz, K. M., Valentino, K., Dri, C. E., & McIntyre, R. S. (2025) · Neurology and Therapy · doi:10.1007/s40120-025-00724-y · Cited by 68
“In addition, preliminary evidence indicates that exenatide may penetrate the BBB at a low concentration, as demonstrated by approximately 1-2% concentration detected in CSF compared to serum levels in persons with PD [29].”
Metadata
- Authors
- Vijiaratnam, N., Girges, C., Auld, G., McComish, R., King, A., Skene, S. S., Hibbert, S., Wong, A., Melander, S., Gibson, R., Matthews, H., Dickson, J., Carroll, C., Patrick, A., Inches, J., Silverdale, M., Blackledge, B., Whiston, J., Hu, M., Welch, J., Duncan, G., Power, K., Gallen, S., Kerr, J., Chaudhuri, K. R., Batzu, L., Rota, S., Jabbari, E., Morris, H., Limousin, P., Greig, N., Li, Y., Libri, V., Gandhi, S., Athauda, D., Chowdhury, K., & Foltynie, T.
- Affiliations
- UCL Queen Square Institute of Neurology (GB)
- University College London (GB)
- University of Surrey (GB)
- Royal Free London NHS Foundation Trust (GB)
- University College Hospital (GB)
- University of Plymouth (GB)
- Manchester Academic Health Science Centre (GB)
- University of Oxford (GB)
- Western General Hospital (GB)
- King's College London (GB)
- National Institute on Aging (US)
- The Francis Crick Institute (GB)
- ORCID
- Vijiaratnam, Nirosen
- Girges, Christine
- McComish, Rachel
- Skene, Simon S
- Dickson, John
- Carroll, Camille
- Inches, Jemma
- Silverdale, Monty
- Welch, Jessica
- Duncan, Gordon
- Batzu, Lucia
- Rota, Silvia
- Jabbari, Edwin
- Morris, Huw
- Limousin, Patricia
- Greig, Nigel
- Li, Yazhou
- Libri, Vincenzo
- Gandhi, Sonia
- Athauda, Dilan
- Chowdhury, Kashfia
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2025-02
- Volume
- 405
- Issue
- 10479
- Pages
- 627-636
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4407121696
- Cited by
- 181
- References
- 32
- Citations by year
- 2026: 111 · 2025: 70
- FWCI
- 110.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- The Lancet (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion, cc-by)
- PEARL (University of Plymouth) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- The Francis Crick Institute (cc-by)
- Funders
- National Institutes of Health
- University College London
- National Institute on Aging
- AstraZeneca
- Cure Parkinson's
- AstraZeneca UK
- UCLH Biomedical Research Centre
- National Institute for Health and Care Research
- University College London Hospitals NHS Foundation Trust
- NIHR Sheffield Clinical Research Facility
- Efficacy and Mechanism Evaluation Programme (16/167/19)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, exenatide, GLP-1 receptor agonists, disease-modifying therapy, disease progression, MDS-UPDRS III, dopaminergic therapy, neuroprotection, Hoehn and Yahr stage
- MeSH terms
- Exenatide, Glucagon-Like Peptide-1 Receptor Agonists, Adult, Aged, Aged, 80 and over, Antiparkinson Agents, Double-Blind Method, Drug Administration Schedule, Female, United Kingdom, Humans, Hypoglycemic Agents, Male, Middle Aged, Parkinson Disease, Peptides, Venoms, Treatment Outcome, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(24)02808-3
- The paper
- Vijiaratnam, N., Girges, C., Auld, G., McComish, R., King, A., Skene, S. S., Hibbert, S., Wong, A., Melander, S., Gibson, R., Matthews, H., Dickson, J., Carroll, C., Patrick, A., Inches, J., Silverdale, M., Blackledge, B., Whiston, J., Hu, M., . . . Foltynie, T. (2025). Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(24)02808-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.